Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07816380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Name: A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer — clinical trial record (NCT07816380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorGuangzhou JOYO Pharma Co., Ltd

Started2026-10-30

View on ClinicalTrials.gov ↗

This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.

Trial Details

NCT Number	NCT07816380
Lead Sponsor	Guangzhou JOYO Pharma Co., Ltd
Conditions	NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment	216 participants
Start Date	2026-10-30
Primary Completion	2028-12-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-15